- Home
- LXRX vs TCPC Comparison
LXRX vs TCPC Comparison
Compare LXRX & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- TCPC
- Stock Information
- Founded
- LXRX 1995
- TCPC 2006
- Country
- LXRX United States
- TCPC United States
- Employees
- LXRX N/A
- TCPC N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- LXRX Health Care
- TCPC Finance
- Exchange
- LXRX Nasdaq
- TCPC Nasdaq
- Market Cap
- LXRX 541.5M
- TCPC 478.8M
- IPO Year
- LXRX 2000
- TCPC 2012
- Fundamental
- Price
- LXRX $1.34
- TCPC $5.70
- Analyst Decision
- LXRX Buy
- TCPC Sell
- Analyst Count
- LXRX 5
- TCPC 2
- Target Price
- LXRX $3.23
- TCPC $6.50
- AVG Volume (30 Days)
- LXRX 2.3M
- TCPC 653.0K
- Earning Date
- LXRX 11-06-2025
- TCPC 11-06-2025
- Dividend Yield
- LXRX N/A
- TCPC 21.48%
- EPS Growth
- LXRX N/A
- TCPC N/A
- EPS
- LXRX N/A
- TCPC N/A
- Revenue
- LXRX $70,864,000.00
- TCPC $219,119,058.00
- Revenue This Year
- LXRX $66.55
- TCPC N/A
- Revenue Next Year
- LXRX N/A
- TCPC N/A
- P/E Ratio
- LXRX N/A
- TCPC N/A
- Revenue Growth
- LXRX 1255.21
- TCPC N/A
- 52 Week Low
- LXRX $0.28
- TCPC $5.39
- 52 Week High
- LXRX $1.66
- TCPC $9.72
- Technical
- Relative Strength Index (RSI)
- LXRX 44.82
- TCPC 46.05
- Support Level
- LXRX $1.36
- TCPC $5.55
- Resistance Level
- LXRX $1.52
- TCPC $5.91
- Average True Range (ATR)
- LXRX 0.13
- TCPC 0.14
- MACD
- LXRX -0.01
- TCPC 0.02
- Stochastic Oscillator
- LXRX 32.61
- TCPC 37.57
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.